Drug intelligence / Profile preview

enzacamene

Development stage
Unknown
Lead developer
Merck KGaA
Modality
Small Molecules
Administration
Topical
01

Overview

Enzacamene is a small molecule organic camphor derivative used as a UV-B filter in sunscreens and cosmetic products to protect the skin from ultraviolet radiation. It is commonly known as 4-methylbenzylidene-camphor (4-MBC). Enzacamene absorbs UV-B rays and dissipates photon energy primarily through cis-trans isomerization, though other photochemical processes also occur due to its low quantum yield for this reaction. It displays weak binding activity at mammalian estrogen receptors and may exert estrogen-like effects via nonclassical signaling mechanisms that do not involve gene regulation by the nuclear estrogen receptor. There are concerns about its potential as an endocrine disruptor, with some evidence suggesting it can affect reproductive hormone levels and possibly suppress the pituitary-thyroid axis in animal studies. Enzacamene is approved for use in Canada but not permitted in the United States or Japan[1][3][4][6].

Brand names
Eusolex 6300Eusolex6300Eusolex-6300Parsol 5000Parsol5000Parsol-5000
Other names
enzacamene4-methylbenzylidene camphor(E)-1,7,7-trimethyl-3-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-2-one
02

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on enzacamene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on enzacamene.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call